Literature DB >> 2662971

High-level expression of self-processed HIV-1 protease in Escherichia coli using a synthetic gene.

Z Hostomsky1, K Appelt, R C Ogden.   

Abstract

A synthetic gene coding for HIV-1 protease (PR) has been constructed and a system for its efficient expression in E. coli has been established: PR is synthesized as a fusion protein with E. coli dihydrofolate reductase under the control of a bacteriophage T7 promoter. The synthetic gene was constructed to enable rapid construction of defined mutants by restriction fragment replacement. A set of mutants has been constructed which may facilitate elucidation of the mechanism of PR self-cleavage from polyprotein precursors. We have demonstrated that the C-terminal residue (Phe99 in the native sequence) of the processing intermediate is absolutely required for subsequent cleavage at the N-terminal cleavage site. The potential structural role of this residue is discussed with reference to the recently published HIV-1 PR structure.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2662971     DOI: 10.1016/0006-291x(89)91350-8

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  12 in total

1.  Reverse transcriptase of human immunodeficiency virus type 1: functionality of subunits of the heterodimer in DNA synthesis.

Authors:  Z Hostomsky; Z Hostomska; T B Fu; J Taylor
Journal:  J Virol       Date:  1992-05       Impact factor: 5.103

2.  Structures of apo and complexed Escherichia coli glycinamide ribonucleotide transformylase.

Authors:  R J Almassy; C A Janson; C C Kan; Z Hostomska
Journal:  Proc Natl Acad Sci U S A       Date:  1992-07-01       Impact factor: 11.205

3.  F99 is critical for dimerization and activation of South African HIV-1 subtype C protease.

Authors:  Previn Naicker; Palesa Seele; Heini W Dirr; Yasien Sayed
Journal:  Protein J       Date:  2013-10       Impact factor: 2.371

4.  Mutagenesis of protease cleavage sites in the human immunodeficiency virus type 1 gag polyprotein.

Authors:  R J Tritch; Y E Cheng; F H Yin; S Erickson-Viitanen
Journal:  J Virol       Date:  1991-02       Impact factor: 5.103

5.  New nucleotide sequence data on the EMBL File Server.

Authors: 
Journal:  Nucleic Acids Res       Date:  1989-11-11       Impact factor: 16.971

6.  HIV-I protease. Cloning, expression, and purification.

Authors:  N I Dergousova; A M Volynskaya; L D Rumsh
Journal:  Appl Biochem Biotechnol       Date:  1996 Oct-Nov       Impact factor: 2.926

7.  Protein structure-based design of potent orally bioavailable, nonpeptide inhibitors of human immunodeficiency virus protease.

Authors:  S H Reich; M Melnick; J F Davies; K Appelt; K K Lewis; M A Fuhry; M Pino; A J Trippe; D Nguyen; H Dawson
Journal:  Proc Natl Acad Sci U S A       Date:  1995-04-11       Impact factor: 11.205

8.  Antiviral and resistance studies of AG1343, an orally bioavailable inhibitor of human immunodeficiency virus protease.

Authors:  A K Patick; H Mo; M Markowitz; K Appelt; B Wu; L Musick; V Kalish; S Kaldor; S Reich; D Ho; S Webber
Journal:  Antimicrob Agents Chemother       Date:  1996-02       Impact factor: 5.191

9.  RNase D, a reported new activity associated with HIV-1 reverse transcriptase, displays the same cleavage specificity as Escherichia coli RNase III.

Authors:  Z Hostomsky; G O Hudson; S Rahmati; Z Hostomska
Journal:  Nucleic Acids Res       Date:  1992-11-11       Impact factor: 16.971

10.  Heterologous expression and purification of active human phosphoribosylglycinamide formyltransferase as a single domain.

Authors:  C C Kan; M R Gehring; B R Nodes; C A Janson; R J Almassy; Z Hostomska
Journal:  J Protein Chem       Date:  1992-10
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.